Trial Profile
Effects of Anti-TSLP on Airway Hyperresponsiveness and Mast Cell Phenotype in Asthma - A Randomized Double-blind, Placebo-controlled Trial of MEDI9929
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2022
Price :
$35
*
At a glance
- Drugs Tezepelumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms UPSTREAM
- 28 May 2021 Primary endpoint has been met. (Supportive primary objective 1: Mannitol test negative in response to treatment with MEDI9929 in patients with asthma)
- 28 May 2021 Primary endpoint has not been met. (Supportive primary objective 3: Decrease in airway hyperresponsiveness to mannitol in response to treatment with MEDI9929 in patients with asthma)
- 28 May 2021 Primary endpoint of decrease in airway hyperresponsiveness to mannitol in response to treatment with MEDI9929 in patients with asthma has not been met, according to results published in the European Respiratory Journal.